摘要:
The instant invention provides methods of expressing polynucleotides in the cells of the liver comprising administering viral particles comprising a recombinant AAV vector into a mammal, preferably a human.
摘要:
The present invention relates to a fusion protein which comprises at least a functional meganuclease and a viral protein and in particular to fusion protein comprising at least a meganuclease, which recognises and cleaves a specific DNA target sequence and a viral peptide selected from the group Vpr and Vpx or a fragment or derivative thereof; wherein said fusion protein is able to associate with Lentivirus vector particles and following transduction into a host cell recognise and cleave said specific DNA target in vivo. The present Patent Application also relates to a viral particle comprising such a fusion protein and to the use of such fusion proteins and viral particles for gene targeting.
摘要:
This invention is directed to nucleic acids derived from the pol region of the genome of human immunodeficiency virus type 1 (HIV-1). The nucleic acids are useful as probes for the detection of HIV-1. More particularly, this invention is directed to nucleic acids encoding a pol region of HIV-1 extending from about nucleotide 1856 to about 1906 and extending from about nucleotide 2048 to about nucleotide 2797.
摘要:
The present invention concerns the endonucleases capable of cleaving a target sequence located in a “safe harbor loci”, i.e. a loci allowing safe expression of a transgene. The present invention further concerns the use of such endonucleases for inserting transgenes into a cell, tissue or individual.
摘要:
The invention relates to an implant obtained by assembling in vitro various elements in order to form a neo-organ which is introduced preferably in the peritoneal cavity of the recipient. The implant comprises a biocompatible support intended to the biological anchoring of cells; cells having the capacity of expressing and secreting naturally or after recombination a predetermined compound, for example a compound having a therapeutical interest; and a constituent capable of inducing and/or promoting the gelling of said cells. The invention also relates to a kit for the preparation of the implant as well as to a new recombinant retroviral vector comprising a provirus DNA sequence modified in that the genes gag, pol and env have been deleted at least partially so as to obtain a proviral DNA capable of replication. The invention also relates to recombinant cells comprising the new retroviral vector.
摘要:
Packaging cell lines useful for the generation of helper-free recombinant retroviruses with amphotropic or ecotropic host ranges, methods of constructing such packaging cell lines and methods of using the recombinant retroviruses to introduce DNA of interest into eukaryotic cells, both in vitro and in vivo.
摘要:
Peptides having the following sequences are disclosed:Leu-Asp-Gln-Phe-Pro-Leu-Gly-Arg-Lys-Phe-Leu,Leu-Asp-Gln-Phe-Pro-Leu-Gly-Arg-Arg-Phe-Leu,Ala-Lys-Arg-Arg-Arg-Lys, andAla-Lys-Lys-Lys-Lys-Lys.
摘要:
The present invention concerns the endonucleases capable of cleaving a target sequence located in a “safe harbor loci”, i.e. a loci allowing safe expression of a transgene. The present invention further concerns the use of such endonucleases for inserting transgenes into a cell, tissue or individual.
摘要:
The present invention provides cell compositions for in vivo implantation, and designed for the sustained and controlled delivery of therapeutic substances.
摘要:
The molecular cloning and characterization of a novel human retrovirus, designated lymphadenopathy-associated virus, or LAV, is disclosed. LAV was originally isolated from a patient with acquired immune deficiency syndrome (AIDS). A cloned LAV complementary DNA (cDNA) was used to screen a library of recombinant phages constructed from the genomic DNA of LAV-infected T lymphocytes. The nucleotide sequence of an insert obtained from the recombinant phage clone &lgr;J19 was ascertained through M13 shotgun cloning and the dideoxy chain termination sequencing method. The env coding region was identified and various hydrophilic peptides obtained therefrom. These peptides correspond to amino acids 551-577, 594-603, 621-630, 657-679, and 719-758 of the LAV envelope glycoprotein. These peptides should provide suitable diagnostic reagents for the detection LAV-specific antibodies and for the generation of LAV-specific immunological reagents.